Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 14;6(12):e801. doi: 10.1097/HS9.0000000000000801

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

Figure 1. — Investigator-assessed progression-free survival. Outcomes are shown for (A) acalabrutinib vs IdR/BR, (B) acalabrutinib vs IdR or BR, (C) acalabrutinib vs IdR/BR by del(17p) and/or TP53 mutation status,^a,b and (D) acalabrutinib vs IdR/BR by IGHV mutation status (ITT population). ^aMutation status for patients with del(17p) were based on values entered manually into IXRS. ^bBecause there were no IdR/BR–treated patients at risk by 42 mo in the del(17p) subgroup based on IXRS data, 42-mo PFS rates were not available for that analysis. ^cHR was based on stratified Cox proportional-hazards model, stratified by randomization stratification factors as recorded in an interactive voice/web response system. ^dP value was based on stratified log-rank test, stratified by randomization stratification factors as recorded in an interactive voice/web response system. ^eHRs were based on unstratified Cox proportional-hazards model. ^fP values were based on unstratified log-rank test. BR = bendamustine plus rituximab; CI = confidence interval; IdR = idelalisib plus rituximab; IGHV = immunoglobulin heavy chain variable region genes; HR = hazard ratio; ITT = intent-to-treat; IXRS = interactive voice/web response system; NR = not reached; mo, months; PFS = progression-free survival; mIGHV = mutated IGHV; TP53m, mutated tumor protein p53; TP53, tumor protein p53; uIGHV = unmutated IGHV.